ICU Medical (NASDAQ:ICUI) Stock

ICU Medical

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

bz_pharma_briefs

News

Health Care

General

ICUI

Smiths Medical, a subsidiary of ICU Medical, recalls ParaPAC Plus P300 and P310 ventilators; they pose risks of injury or death.

ICU Medical Recalls ParaPAC Plus Ventilators Due To Loose Outlet Connector That Can Cause Injury Or Death

ICU Medical Recalls Certain Tracheostomy Tubes Due To Manufacturing Defects

movers image

Intraday Update

Markets

Movers

Trading Ideas

AXGN

BOOT

CLNE

COMM

DCGO

FWRD

KVYO

LESL

NVMI

VSAT

XPEL

YETI

Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday

ICU Medical Inc

In the preceding three months, 4 analysts have released ratings for ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $197.5, along with a high estimate of $209.00 and a low estimate of $183.00. This current average has increased by 14.49% from the previous average price target of $172.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1733947242_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive ICU Medical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$198.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$183.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ICU Medical's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of ICU Medical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>Delving into ICU Medical's Background</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>Understanding the Numbers: ICU Medical's Finances</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, ICU Medical showcased positive performance, achieving a revenue growth rate of 6.47% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ICU Medical's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.6%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ICU Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.61%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ICU Medical's ROA excels beyond industry benchmarks, reaching -0.77%. This signifies efficient management of assets and strong financial health.
Debt Management: ICU Medical's debt-to-equity ratio is below the industry average. With a ratio of 0.81, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

A Glimpse Into The Expert Outlook On ICU Medical Through 4 Analysts

Jefferies analyst Michael Toomey upgrades ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) from Hold to Buy and announces $200 price target.

Upgrades

Price Target

Jefferies Upgrades ICU Medical to Buy, Announces $200 Price Target

During the last three months, 4 analysts shared their evaluations of ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $195.0, a high estimate of $209.00, and a low estimate of $183.00. This upward trend is apparent, with the current average reflecting a 16.3% increase from the previous average price target of $167.67.
<img src="https://www.benzinga.com/files/images/story/2024/1731513647_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of ICU Medical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$209.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$198.00</td>
<td>$147.00</td>
</tr>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$183.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$158.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ICU Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>Delving into ICU Medical's Background</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>ICU Medical: A Financial Overview</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, ICU Medical showcased positive performance, achieving a revenue growth rate of 8.58% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: ICU Medical's net margin excels beyond industry benchmarks, reaching -3.59%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): ICU Medical's ROE excels beyond industry benchmarks, reaching -1.04%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): ICU Medical's ROA stands out, surpassing industry averages. With an impressive ROA of -0.5%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: ICU Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.82.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down ICU Medical: 4 Analysts Share Their Views

Keybanc analyst Brett Fishbin maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Overweight and raises the price target from $198 to $209.

Keybanc Maintains Overweight on ICU Medical, Raises Price Target to $209

Needham analyst Mike Matson reiterates ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Hold.

Reiteration

Needham Reiterates Hold on ICU Medical

The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market.
<ul>
<li>Joint venture becomes part of a global manufacturing network with scale and redundancy</li>
<li>Intends to add long-term supply resiliency and accelerate IV solutions new product development in North America</li>
<li>Combines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distribution</li>
<li>ICU Medical to provide commercial services to the joint venture</li>
<li>Expected to become operationally effective in early Q2 2025</li>
<li>Full presentation available for view <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4300832-1&amp;h=1684507301&amp;u=https%3A%2F%2Fir.icumed.com%2Fpresentations&amp;a=here">here</a></li>
</ul>
SAN CLEMENTE, Calif. and TOKUSHIMA, Japan, Nov. 12, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4300832-1&amp;h=3638334367&amp;u=https%3A%2F%2Fwww.icumed.com%2F&amp;a=ICU+Medical%2C+Inc.">ICU Medical, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), global IV solutions manufacturing subsidiary of Otsuka Holdings Co., Ltd., together announce the creation of a joint venture to provide additional supply chain resiliency and innovation to the North American IV solutions market.

Biotech

ICU Medical And Otsuka Pharmaceutical Factory A Subsidiary Of Otsuka Holdings Co. Announce Creation Of A Joint Venture To Bolster IV Solutions Manufacturing And Innovation In North America

For Fiscal Year 2024 the Company updated its estimates of GAAP net loss from a range of $(118) to $(108) to a range of $(130) to $(122) and GAAP diluted loss per share from a range of $(4.78) to $(4.38) to a range of $(5.28) to $(4.98).&nbsp;
The Company updated the estimated range of its full year 2024 guidance of adjusted EBITDA from a range of $345 million to $365 million to a range of $355 million to $365 million

Guidance

ICU Medical Updates FY24 Adj EPS Outlook From $4.95 - $5.35 To $5.40 -$5.70, Est $5.22

ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) reported quarterly earnings of $1.59 per share which beat the analyst consensus estimate of $1.25 by 27.2 percent. This is a 1.27 percent increase over earnings of $1.57 per share from the same period last year. The company reported quarterly sales of $589.13 million which beat the analyst consensus estimate of $574.70 million by 2.51 percent. This is a 6.47 percent increase over sales of $553.31 million the same period last year.

Earnings

Earnings Beats

ICU Medical Q3 2024 Adj EPS $1.59 Beats $1.25 Estimate, Sales $589.13M Beat $574.70M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Keybanc analyst Brett Fishbin maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Overweight and raises the price target from $147 to $198.

Keybanc Maintains Overweight on ICU Medical, Raises Price Target to $198

4 analysts have expressed a variety of opinions on ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for ICU Medical, presenting an average target of $169.5, a high estimate of $190.00, and a low estimate of $147.00. Marking an increase of 18.53%, the current average surpasses the previous average price target of $143.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1728910836_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive ICU Medical is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Toomey</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$183.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$158.00</td>
<td>$135.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of ICU Medical's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>Delving into ICU Medical's Background</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>Financial Insights: ICU Medical</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining ICU Medical's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.58% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.59%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ICU Medical's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.04%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): ICU Medical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: ICU Medical's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.82.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 4 Ratings For ICU Medical

Jefferies analyst Michael Toomey initiates coverage on ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Hold rating and announces Price Target of $183.

Initiation

Jefferies Initiates Coverage On ICU Medical with Hold Rating, Announces Price Target of $183

Management

ICU Medical Appointed Daniel Woolson As President

FDA Says Smiths Medical Issues Correction For ParaPAC Plus P300 And P310 Ventilators Due To Inadvertent Tidal Volume Knob Movement; Recall Involves Correcting Devices Without Removing Them From Use Or Sale

ICU Medical Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) subsidiary, Smiths Medical, initiated a <a href="https://www.fda.gov/medical-devices/medical-device-recalls/ventilator-recall-smiths-medical-removes-parapac-plus-ventilators-due-loosened-or-detached-patient">recall</a> Friday of its paraPAC plus P300 and P310 ventilators <a href="https://www.benzinga.com/topic/medical-devices">due to faulty parts</a>. 
According to the FDA, there&#8217;s a possibility that the patient outlet connector may loosen or detach, impacting active ventilation. If this happens, it could cause serious adverse health consequences, including not enough ventilation (hypoventilation), not enough oxygen (hypoxia), slowed heartbeat (bradycardia), low blood pressure (hypotension), a sudden stop of the lungs (respiratory arrest), and death.
There has been one reported injury. There has been one report of death.
Smiths Medical PneuPAC paraPAC Plus P300 and P310 Ventilators are gas-powered emergencies and transport portable ventilators, including in vehicles such as airplanes and helicopters.
They are suitable for emergencies at accident scenes and transports between hospitals or within a hospital or medical facility. These ventilators are intended to provide ventilatory support for adults, children, and infants.
The paraPAC Plus devices also provide free-flow oxygen therapy and continuous positive airway pressure (CPAP) therapy for spontaneously breathing patients. They can also be used in emergency situations to provide ventilatory support for CPR resuscitation.
Earlier this week, Smiths Medical initiated a <a href="https://www.fda.gov/medical-devices/medical-device-recalls/tracheostomy-tube-recall-smiths-medical-removes-certain-bivona-neonatalpediatric-and-adult">recall</a> of certain Bivona neonatal/pediatric and adult tracheostomy tubes due. A manufacturing defect caused the securement flange on the <a href="https://www.benzinga.com/news/24/09/40943574/icu-medical-recalls-certain-tracheostomy-tubes-due-to-manufacturing-defects" target="_blank" rel="noreferrer noopener">device to tear</a>. There have been 35 reported injuries and two reported deaths.
Price Action: ICU Medical stock is down 1.56% at $178.44 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40962425/jp-morgan-targets-uk-with-fresh-credit-card-offering-report" target="_blank" rel="noreferrer noopener">JPMorgan Targets UK With Fresh Credit Card Offering: Report</a></li>
</ul>

FDA Says Smiths Medical Recalls Parapac Plus Ventilators Due To Loosened Patient Outlet Connector, One Injury And One Death Reported, Classified As Most Serious Recall

On Wednesday, ICU Medical Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) subsidiary, Smiths Medical, initiated a recall of certain Bivona neonatal/pediatric and adult tracheostomy tubes.
The FDA classified the <a target="_blank" href="https://www.fda.gov/medical-devices/medical-device-recalls/tracheostomy-tube-recall-smiths-medical-removes-certain-bivona-neonatalpediatric-and-adult" rel="noreferrer noopener">recall</a> as the most serious type, which could cause severe injury or death.
Smiths Medical is recalling specific lots of Bivona Neonatal/Pediatric and Adult Tracheostomy tubes due to a manufacturing defect that may cause the securement flange of the device to tear.
Affected products include:
<ul>
<li>Bivona Aire-Cuf, TTS, Uncuffed, Mid-Range Neonatal/Pediatric Tracheostomy Tubes.</li>
<li>Bivona Aire-Cuf, TTS, Cuffless FlexTend, TTS FlexTend Adult Tracheostomy Tubes.</li>
</ul>
The use of affected products may cause serious adverse health consequences, including lack of proper ventilation, loss of a protected airway, and death.&nbsp;
There have been 35 reported injuries. There have been two reports of death.&nbsp;&nbsp;
Bivona neonatal/pediatric and adult&nbsp;tracheostomy&nbsp;tubes provide direct airway access for up to 29 days for a patient with a tracheostomy,&nbsp;a surgical procedure that creates an opening in the neck and into the windpipe (trachea) to help a person breathe.
Some tubes can be reprocessed and reused several times for a single patient.&nbsp;
The company said not to use the Bivona tracheostomy tubes from the affected lot numbers. They should be thrown away.&nbsp;
Price Action: At last check Thursday, ICUI stock was up 2.25% at $180.19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/09/40927367/zimmer-biomet-to-stop-selling-cpt-hip-implant-system-by-end-of-2024-due-to-high-fracture-risks" target="_blank" rel="noreferrer noopener">Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks</a>.</li>
</ul>

In the preceding three months, 4 analysts have released ratings for ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $157.5, a high estimate of $190.00, and a low estimate of $135.00. Observing a 10.14% increase, the current average has risen from the previous average price target of $143.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1726146088_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive ICU Medical. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$136.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$158.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$135.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to ICU Medical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ICU Medical compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ICU Medical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ICU Medical's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ICUI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on ICU Medical analyst ratings.</a>
<h2>About ICU Medical</h2>
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.
<h3>ICU Medical: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Revenue Growth: ICU Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 8.58%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.59%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ICU Medical's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.04% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): ICU Medical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.5%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.82, ICU Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into ICU Medical Stock: Analyst Perspectives (4 Ratings)

Raymond James analyst Jayson Bedford maintains ICU Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICUI#NASDAQ">ICUI</a>) with a Outperform and raises the price target from $158 to $190.

Raymond James Maintains Outperform on ICU Medical, Raises Price Target to $190

Press Releases

ICU Medical Announces Time of Second Quarter 2024 Earnings Conference Call

ICU Medical Announces Second Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance

ICU Medical to Participate in Upcoming Investor Conferences

ICU Medical Announces Time of Third Quarter 2024 Earnings Conference Call

ICU Medical to Participate at the UBS Global Healthcare Conference

ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc., a Subsidiary of Otsuka Holdings Co. Ltd., Announce Creation of a Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America

ICU Medical Announces Third Quarter 2024 Results and Updates Its Fiscal Year 2024 Guidance

ICU Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ICU Medical Announces Time of Fourth Quarter 2024 Earnings Conference Call

ICU Medical to Present at the Raymond James 46th Annual Institutional Investors Conference

Comments

ICU Medical

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga